• Empower Clinics (CBDT) has received mobile testing accreditation through the College of Physicians and Surgeons of BC Diagnostic Accreditation Program (DAP) 
  • The accreditation allows Empower to offer mobile testing solutions at any location a client desires
  • Chairman & CEO Steven McAuley sat down with Folake Ekwubiri to discuss the news
  • Empower is an integrated healthcare company that provides digital and telemedicine care
  • Empower Clinics Inc. (CBDT) opened trading at C$0.10 per share

Empower Clinics (CBDT) has received accreditation for its COVID-19 mobile testing solutions.

The accreditation was granted by the College of Physicians and Surgeons of BC Diagnostic Accreditation Program (DAP).

The mobile services accreditation allows Empower to offer mobile testing solutions at any location a client requires, including hotels, cruise ships, workplaces or conference venues.

Steven McAuley, Chairman and CEO of Empower Clinics sat down with Folake Ekwubiri to highlight the updates.

“With this newly certified mobile service, Empower Clinics is clearly the leader in offering the most convenient and fully certified COVID-19 testing solutions in and around the Port of Vancouver. Our significant effort and investment to achieve all the necessary accreditation is a reflection of our commitment to the highest possible quality and integrity on behalf of the travel industry. Cruise lines, tour companies and their guests should not be burdened with the liability of using unaccredited services.”

Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, a medical device company and world-class medical diagnostics laboratories. Empower is aggressively growing its clinical and digital presence across North America.

Empower Clinics Inc. (CBDT) opened trading at C$0.10 per share.

 

More From The Market Online
stock market down

@ the Bell: TSX hits near-month high

The TSX rose near highs not seen in a month, but a split between indices capped gains as mining and energy were the only…

FSD Pharma submits MS treatment clinical trial for review in Australia

FSD Pharma (CSE:HUGE) submits its MS treatment's Phase-1 Multiple Ascending Doses Clinical Trial Application for ethics review in Australia.
Pinnacle Silver and Gold - Shot from Pinnacle Silver and Gold's Argosy Gold Project in Ontario.

This junior gold stock is at an all-time low and ready to rally

Junior gold investors currently enjoy dozens of opportunities with multi-bagger upside with stocks at or near all-time lows.

This small-cap gold stock keeps notching high-grade gold in Nevada 

Viva Gold (TSXV:VAU) continues to capitalize on the market thanks to its 100-per-cent-owned Tonopah project in west-central Nevada.